STOCK TITAN

Twist Bioscience insider files Form 144 to sell 238 shares on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice from Twist Bioscience (TWST) shows an insider sale filing for common stock. The filer plans to sell 238 shares via Fidelity Brokerage Services on NASDAQ with an aggregate market value of $6,179.48 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 through restricted stock vesting and were received as compensation. The filing lists four prior small common-stock sales by Robert Werner totaling 1,492 shares between 05/21/2025 and 08/04/2025 with gross proceeds reported for each sale. The notice includes the standard certification that the signer is unaware of undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small, routine insider sale from recently vested restricted stock; no material red flags in the filing.

The filing documents a proposed sale of 238 shares valued at $6,179.48 by an insider through Fidelity on NASDAQ, with acquisition dated 08/20/2025 via restricted stock vesting and payment characterized as compensation. Historical disposals by the same person total 1,492 shares across four trades earlier in 2025, with gross proceeds reported per trade. The sizes and timing suggest routine monetization of vested compensation rather than large-scale divestiture. The filing contains the standard attestation regarding knowledge of material nonpublic information.

TL;DR: Disclosure is complete for Rule 144 purposes; documentation shows compensation-related vesting followed by planned sales.

The Form 144 provides required elements: number of shares, acquisition date and nature (restricted stock vesting), broker details, planned sale date, and prior sales in the past three months. All listed transactions are relatively small in absolute terms and tied to compensation. The signature/attestation language is present. The filing does not disclose any material adverse facts or trading-plan adoption dates.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TWST Form 144 filed for 08/21/2025 disclose?

It discloses a proposed sale of 238 common shares valued at $6,179.48 through Fidelity on NASDAQ, acquired 08/20/2025 via restricted stock vesting.

Who acquired the securities being sold according to the filing?

The securities were acquired from the issuer on 08/20/2025 as restricted stock vesting and were paid as compensation.

Has the seller made other sales of TWST stock recently?

Yes. The filing lists four prior sales by Robert Werner on 05/21/2025, 05/23/2025, 06/06/2025, and 08/04/2025 totaling 1,492 shares with reported gross proceeds per trade.

What broker will execute the planned sale in the Form 144?

Fidelity Brokerage Services LLC (900 Salem Street, Smithfield RI 02917) is named as the broker for the 238-share sale.

Does the filing indicate any undisclosed material information about the company?

No. The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.54B
60.26M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO